Kabra Drugs Ltd

BSE : Kabra_Drugs13 Jan 2025

Pharmaceuticals

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Kabra Drugs Ltd

Kabra Drugs Ltd

Pharmaceuticals

BSE : Kabra_Drugs13 Jan 2025

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Cash flow

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
04-Dec-2024	BC	Approved the Notice of the Extra-Ordinary General to be held on Thursday, January 2, 2025. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, The Notice of EGM of the Company to held	02-Jan-2025
25-Nov-2024	BC	Inter alia to consider and approve the following matters: 1. To consider and approve proposal of fund raising by issue of equity shares or any other permitted mode, through Preferential Allotment/Pri	04-Dec-2024
07-Nov-2024	BC	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve This is to inform you that the meeting of the	14-Nov-2024
21-Oct-2024	BC	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Board of Directors of Company will be held on	04-Nov-2024
02-Sep-2024	BC	Board of Directors of the company was held today viz Monday, 2nd September 2024 at registered office at 5:00 P.M. and concluded at 8:00 P.M. 35th AGM Scrutinizer''s Report (As Per BSE Announce	30-Sep-2024

No Rights has been declared by Kabra_Drugs

Book Closure

Record Date	Split Date	Purpose
02-Jan-2025	-	Approved the Notice of the Extra-Ordinary General to be held on Thursday, January 2, 2025. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, The Notice of EGM of the Company to held
04-Dec-2024	-	Inter alia to consider and approve the following matters: 1. To consider and approve proposal of fund raising by issue of equity shares or any other permitted mode, through Preferential Allotment/Pri
14-Nov-2024	-	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve This is to inform you that the meeting of the
04-Nov-2024	-	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Board of Directors of Company will be held on
30-Sep-2024	-	Board of Directors of the company was held today viz Monday, 2nd September 2024 at registered office at 5:00 P.M. and concluded at 8:00 P.M. 35th AGM Scrutinizer''s Report (As Per BSE Announce

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Kabra Drugs Ltd ₹10.06(0.00/0.00%)	10.06	+0.00	10.14	61.74	0.00	3.09
Bliss GVS Pharma Ltd ₹161.55(+0.40/0.25%)	161.55	+0.40	1,702.19	29.03	21.06	1.66
Amrutanjan Health Care Ltd ₹696.00(+1.20/0.17%)	696.00	+1.20	2,012.18	16.36	42.34	6.76
Astrazeneca Pharma India Ltd ₹6,913.95(+117.85/1.73%)	6,913.95	+117.85	17,284.88	9.64	134.28	25.44
Abbott India Ltd ₹27,951.80(+640.70/2.35%)	27,951.80	+640.70	59,397.58	8.62	46.24	16.87
Ambalal Sarabhai Enterprises Ltd ₹49.82(-1.23/-2.41%)	49.82	-1.23	381.79	-1.81	43.32	8.47

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Cash and Cash Equivalents at Beginning of the year	0.00	0.00	0.01	0.01	0.01
Net Cash from Operating Activities	-0.21	-0.35	-0.13	-0.25	-0.05
Net Cash Used In Investing Activities	0.00	0.00	0.00	0.00	0.06
Net Cash Used In Financing Activities	2.88	0.36	0.13	0.25	-0.02
Net Inc./Dec In Cash And Cash Equivalents	2.67	0.00	-0.01	0.00	0.00
Cash And Cash Equivalents At End Of The Year	2.67	0.00	0.00	0.01	0.01

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

0.00%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

100.00%

**Promoter pledged shareholding 0.00%

About Kabra Drugs Ltd

Kabra Drugs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 10.14 crores. It has reported a sales of Rs. 0 crores and a net profit of Rs. -0.4 crores for the quarter ended December 2018. The company management includes , B V Anatha Kumar,Ananthkumar Shilpa,KUNIAMUTHUR NANJAPPAN ANAND,Monika Sanwal,A Anitha,N Aravind (Kabra Drugs Ltd) among others.

Chairman

Registered office

270 Shastri Market Indore,,Indore,Madhya Pradesh,452007

FAX :

Background

Incorporation Year1989

Face Value₹10

Market Lot1